In the first completed clinical trial of CAR-NK cells for AML, NK92 MI cells engineered with CD33-CAR and constitutively secreting human IL2 were utilized in three patients with r/r AML co-managed with salvage chemotherapy (NCT02944162) [62]. Here, CD33 is linked to acute myeloid leukemia.